Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1140251 | 0.99 | MAPK14 (0.81) | MAPK14 | |
| SCHEMBL1140249 | 0.97 | MAPK14 (0.78) | MAPK14 | |
| SCHEMBL1139854 | 0.97 | MAPK14 (0.78) | MAPK14 | |
| SCHEMBL1140379 | 0.97 | MAPK14 (0.83) | MAPK14 | |
| SCHEMBL1140336 | 0.93 | MAPK14 (0.72) | MAPK14 | |
| SCHEMBL1140334 | 0.91 | MAPK14 (0.77) | MAPK14 | |
| Azd-6703 SCHEMBL29367099 | 0.91 | MAPK14 (1.00) | MAPK14 | |
| Azd-6703 SCHEMBL1140074 | 0.91 | MAPK14 (1.00) | MAPK14 | |
| Azd-6703 SCHEMBL1140651 | 0.90 | MAPK14 (0.98) | MAPK14 | |
| SCHEMBL1139851 | 0.90 | MAPK14 (0.85) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682520-B1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-02-23 | — | — | EP | claimed |
| US-7750154-B2 | Amide derivatives | ASTRAZENECA AB (SE) | 2010-07-06 | — | — | US | claimed |
| JP-2007509118-A | — | — | 2007-04-12 | — | — | JP | claimed |
| US-20070043065-A1 | Amide derivatives | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | claimed |
| EP-1682520-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2006-07-26 | — | — | EP | claimed |
| WO-2005042502-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-05-12 | — | — | WO | claimed |
| EP-1682520-B1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-02-23 | — | — | EP | disclosed |
| US-7750154-B2 | Amide derivatives | ASTRAZENECA AB (SE) | 2010-07-06 | — | — | US | disclosed |
| US-20070043065-A1 | Amide derivatives | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
| EP-1682520-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005042502-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043065-A1 | Amide derivatives | IL6, IL2, IL1B | MAPK14 2518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.